Ultraviolet-A1 irradiation therapy for systemic lupus erythematosus

H McGrath Jr
Veterans Administration, New Orleans, LA, USA

Systemic lupus erythematosus (lupus, SLE) is a chronic autoimmune disease characterized by the production of autoantibodies, which bind to antigens and are deposited within tissues to fix complement, resulting in widespread systemic inflammation. The studies presented herein are consistent with hyperpolarized, adenosine triphosphate (ATP)-deficient mitochondria being central to the disease process. These hyperpolarized mitochondria resist the depolarization required for activation-induced apoptosis. The mitochondrial ATP deficits add to this resistance to apoptosis and also reduce the macrophage energy that is needed to clear apoptotic bodies. In both cases, necrosis, the alternative pathway of cell death, results. Intracellular constituents spill into the blood and tissues, eliciting inflammatory responses directed at their removal. What results is “autoimmunity.” Ultraviolet (UV)-A1 photons have the capacity to remediate this aberrancy. Exogenous exposure to low-dose, full-body, UV-A1 radiation generates singlet oxygen. Singlet oxygen has two major palliative actions in patients with lupus and the UV-A1 photons themselves have several more. Singlet oxygen depolarizes the hyperpolarized mitochondrion, triggering non-ATP-dependent apoptosis that deters necrosis. Next, singlet oxygen activates the gene encoding heme oxygenase (HO-1), a major governor of systemic homeostasis. HO-1 catalyzes the degradation of the oxidant heme into biliverdin (converted to bilirubin), Fe, and carbon monoxide (CO), the first three of these exerting powerful antioxidant effects, and in conjunction with a fourth, CO, protecting against injury to the coronary arteries, the central nervous system, and the lungs. The UV-A1 photons themselves directly attenuate disease in lupus by reducing B cell activity, preventing the suppression of cell-mediated immunity, slowing an epigenetic progression toward SLE, and ameliorating discoid and subacute cutaneous lupus. Finally, a combination of these mechanisms reduces levels of anticardiolipin antibodies and protects during lupus pregnancy. Capping all of this is that UV-A1 irradiation is an essentially innocuous, highly manageable, and comfortable therapeutic agency. Lupus (2017) 26, 1239–1251.

Key words: Ultraviolet-A1; apoptosis; anticardiolipin antibodies; B-cells; pulmonary hypertension; interstitial lung disease; coronary artery disease; carbon monoxide; heme oxygenase-1; discoid lupus; subacute cutaneous lupus erythematosus

Introduction

Falling within the electromagnetic spectrum between X-rays and visible light, the ultraviolet (UV) spectrum is conventionally divided into wavelength bands of increasing length and decreasing energy. Vacuum UV (<200 nm), UV-C (200–280 nm), UV-B (280–320 nm) and UV-A (320–400 nm) comprise the spectrum. The UV-A band has been further divided into UV-A2 (320–340 nm) and UV-A1 (340–400 nm) because UV-A2 shares properties with UV-B1 and UV-A1 has properties that overlap with visible light. Different chromophores (photon-absorbing molecules) absorb different UV wavelengths, determining their photo-biological effects. These differences account for the healing action of UV-A1 wavelengths when contrasted with the noxious effects of the shorter UV wavelengths in patients with lupus.3–14

The primary target of UV photons is the skin. The shortest terrestrial band of wavelengths, UV-B,
penetrates to the superficial papillary dermis, deep enough to be absorbed by and do damage to epidermal DNA. The DNA damage alters gene translation and function and in lupus triggers anti-double-stranded DNA (anti-dsDNA) antibody production. Repair of the DNA draws on compromised adenosine triphosphate (ATP) stores for repair. In addition, the shorter UV wavelengths such as UV-B suppress cell-mediated immunity (CMI), already suppressed in systemic lupus erythematosus (SLE), and these wavelengths promote antigen translocation, a phenomenon that leads to epidermal cell lysis in patients with lupus.

In contrast, UV-A1 photons, which are not absorbed by DNA, penetrate deeply to reach the high levels of immunoreactants observed in the dermal-epidermal junction. Inasmuch as overflow of these immunoreactants into the blood and tissues accounts for much of the systemic expression of disease in patients with SLE, the modulatory effect of UV-A1 photons similarly reaches every organ system.

**Early investigations**

The mitigating effects of the longest wavelengths of UV radiation on a systemic disease were first observed in a study using the New Zealand Black/New Zealand White (NZB/NZW) mouse model of lupus. In this animal, the UV-A wavelengths not only lacked the toxicity of UV-B wavelengths but unexpectedly attenuated disease activity. UV-A radiation reversed the reduced lymphocyte mitogen responsiveness, decreased the extent of spleen enlargement, reduced the levels of anti-dsDNA antibodies and promoted the survival of the treated mice during the study period, as all of their untreated littersmates died along the usual mortality curve for this model. As shown in a follow-up study, the longest UV-A wavelengths comprising the UV-A1 band were responsible for this salutary outcome.

Human studies followed. TL10R Philips lamps, fitted with filters that transmit only UV-A1 wavelengths, were employed. In a series of studies, low-dose, full-body UV-A1 irradiation significantly decreased disease activity (systemic lupus activity measure (SLAM)) scores of patients with lupus (Figure 1), inducing an early reversal of fatigue, depression, and cognitive dysfunction and subsequently decreasing the inflammatory symptoms of pleurisy, joint pain, and mouth ulcers.

Photosensitivity exhibited the latest response. The effectiveness persisted and even increased nonsignificantly with less-frequent weekly therapy over several years (Figure 2).

**Apoptosis and UV-A1**

Apoptosis, or programmed cell death, is the ordered destruction and safe disposal of cells by macrophages and immature dendritic cells. The efficient activation of apoptosis is critical for the maintenance of homeostasis, the avoidance of necrosis, and the removal of excess T and B cells to terminate an immune response. The resulting apoptotic bodies must be quickly cleared to avoid necrosis and prevent coagulation.

Apoptosis is flawed in patients with lupus. The mitochondria, centers of energy production and governors of intrinsic apoptosis, are abnormal, exhibiting hyperpolarization and ATP deficits. The hyperpolarized ATP-deficient mitochondria resist the depolarization required to initiate activation-induced apoptosis. Overexpression of the BCL-2 family of genes, which similarly inhibits activation-induced apoptosis, further increases the mitochondrial resistance to depolarization.
These changes result in a shift toward the default mechanism of necrosis, or to spontaneous apoptosis, the latter possibly an escape from the mitochondrial block.

This failure to complete apoptosis and the lack in sufficient mitochondrial ATP to fuel macrophages both predispose to necrosis. Necrosis is a toxic form of cell death caused by the release of autologous cell constituents into the blood and surrounding interstitial tissues. These self-or auto-constituents elicit a dendritic cell-coordinated T and B cell-mediated inflammatory immune response directed at preventing the escape of these auto-constituents into the blood and tissues. This protective inflammatory immune response is an autoimmune response as it is the released auto-constituents that drive it.

In contrast to these actions, UV-A1-generated singlet oxygen elicits a state of intense oxidative stress sufficient to activate the intrinsic apoptotic pathway by opening the mitochondrial megapores in the outer mitochondrial membrane. This results in a collapse of the electrochemical gradient across the membrane and the subsequent release of apoptosis-initiating factors and cytochrome C, inducing immediate or pre-programmed apoptosis.

This apoptotic mechanism is not ATP dependent, fostering, when added to the singlet oxygen-induced activation of energy-generating autophagy, a restoration of the diminished phagocytic cell ATP reserves required for the macrophage-mediated clearance of apoptotic bodies.

Through the ATP-sparing induction of apoptosis and perhaps its activation of energy-generating autophagy, UV-A1 irradiation compensates for a low intracellular ATP/adenosine diphosphate (ADP) ratio. In this manner, UV-A1 photons protect against the decreases in macrophage energy required to clear apoptotic bodies. In addition, these photons reduce the overexpression of BCL-2, an inhibitor of apoptosis.

The drugs currently used to treat lupus highlight the central role of apoptosis, as virtually all are proapoptotic. These include glucocorticoids, cytotoxic agents, hydroxychloroquine, mycophenolic acid, and belimumab. Drugs with the opposite action support this paradigm, estrogens and tumor necrosis factor inhibitors facilitating the development of lupus.

B cells

Interferon-gamma (IFN-gamma), which induces the release of soluble B-lymphocyte stimulator (sBLyS) by monocytes/macrophages, is overexpressed in peripheral T cells in patients with lupus. sBLyS contributes to the immunopathogenesis of lupus by promoting B cell activation and maturation and by inhibiting B cell apoptosis. Increased expression of the sBLyS mRNA directly correlates with increased disease activity in patients with SLE. Low-dose, full-body UV-A1 irradiation-induced singlet oxygen production suppresses the secretion of IFN-gamma secretion and parallels the UV-A1-induced mitigation of clinical disease activity in patients with lupus.

In vitro, in vivo, and ex vivo studies all support the UV-A1-induced suppression of B cells and B cell activity. In vitro, UV-A1 causes pronounced non-nuclear damage, including cytoskeletal damage. Ex vivo, UV-A1 photons decreases B cell activity; 2 J/cm² of UV-A1 irradiation delivered through normal skin obtained from cosmetic breast reduction surgery killing 20% of T and B cells and decreasing immunoglobulin (IgG, IgM, IgA, and IgE) production. In vivo, as mentioned above, singlet oxygen acts to suppress IFN-gamma secretion.
Urocanic acid (UCA)

Although UV-A1 photons suppress humoral immunity, they have the opposite effect on CMI,\textsuperscript{57,58} abnormally suppressed in patients with SLE.\textsuperscript{59} Exposure to sunlight, which further suppresses lupus-suppressed CMI, may partially account for the toxicity of sunlight in patients with the disease.\textsuperscript{60,61} The short solar wavelengths, UV-B and UV-A2, are responsible for the suppression. UV-A1 wavelengths block this suppression\textsuperscript{62,63} and even reverse it.\textsuperscript{64} This is reminiscent of the NZB/NZW mouse model, in which UV-A1 wavelengths increased CMI and reduced disease activity.\textsuperscript{3,4} The contrasting actions of UV-B and UV-A1 wavelengths on CMI parallel the contrasting toxic and remedial actions of UV-B and UV-A1 wavelengths on humans and animals with lupus, suggesting that UCA plays a role in the disease.

UCA is a natural sunscreen that protects against DNA damage. It constitutes approximately 0.05% of the dry weight of the epidermis in humans,\textsuperscript{65} reflecting its vital biological role. Solar UV-B photons isomerize UCA from its resting trans-form to the active cis-isomer, which suppresses CMI. Even the UV-B photons emitted from uncovered fluorescent lamps isomerize UCA to its active cis isomer\textsuperscript{13} in vitro and increase disease activity in vivo.\textsuperscript{66} Teleologically, the suppression of CMI may serve to protect against solar-mediated actinic changes that would predispose patients to immune-mediated rashes and pruritus with every sun exposure. In patients with lupus, who are already CMI suppressed, this added suppression appears to be counter-productive, exacerbating disease activity.

UV-A1 photons first reverse the UV-B (i.e. cis-UCA)-induced suppression of CMI through oxidative destruction of cis-UCA by singlet oxygen\textsuperscript{67} and then through the singlet oxygen-induced expression of the gene encoding heme oxygenase-1 (HO-1), an enzyme that releases CO, a mediator capable of abrogating the suppression of CMI. CO does this by binding and stimulating soluble guanylyl cyclase, a catalyst for the synthesis of cyclic guanosine monophosphate (cGMP).\textsuperscript{68,69} Increased cGMP levels parallel the decreases in cis-UCA-induced suppression of CMI.\textsuperscript{70}

The reason for the innate suppression of CMI in patients with lupus remains unknown. However, because UV-A1 photons, which reverse the suppression, mitigate disease, CMI seems key in disease pathogenesis.

Epigenetics

Epigenetics pertains to environmental influences that modify gene expression without changing the genomic DNA. UV-A1 and UV-B photons have opposing epigenetic effects on patients with SLE. Only 25%–45% of monozygotic twins of a patient with lupus develop the disease, suggesting that the environment regulates changes in the DNA. This has resulted in what is designated twin discordance.\textsuperscript{71} The reasons for this discordance are attributed to a number of factors; the principal factor is a deficit in DNA methylation, a reaction that suppresses unwarranted gene expression.\textsuperscript{72} Global deficits in DNA methylation are observed in T and B cells from patients with lupus,\textsuperscript{73–75} but not CD8\textsuperscript{+}.\textsuperscript{76} T lymphocytes display this hypomethylation,\textsuperscript{75,76} the degree of which correlates with disease activity and anti-dsDNA antibody levels.\textsuperscript{77,78} Mice injected with CD4\textsuperscript{+} cells that have been chemically demethylated exhibit a lupus-like syndrome.\textsuperscript{79,80} Even individuals with drug-induced lupus exhibit hypomethylation.\textsuperscript{81} The reduced gene methylation in T cells, B cells, and mononuclear cells from patients with lupus renders the patients hypersensitive to IFN-induced inflammation,\textsuperscript{82} a hypersensitivity that is preserved through the active stages of the disease and is consistent with the chronic, recurrent nature of SLE.\textsuperscript{82}

UV-A1 irradiation counteracts this demethylation of genes in patients with lupus;\textsuperscript{78} UV-A1 photons remethylate genes and have even been implicated in global DNA hypermethylation.\textsuperscript{83} Accordingly, full-body UV-A1 irradiation has the potential for reversing what may be a major disease mechanism in lupus, i.e. gene demethylation. Not surprisingly, UV-B irradiation, well known to enhance disease activity in lupus, promotes hypomethylation of CD4\textsuperscript{+} T cell genes in patients with lupus.\textsuperscript{84}

HO-1

HO-1 is a powerful homeostatic enzyme that releases products with antioxidant, immunosuppressive, anti-inflammatory, antithrombotic, cytoprotective, and pro-survival actions.\textsuperscript{85–87} Its deficiency exacerbates disease states. It is expressed at low levels in patients with lupus,\textsuperscript{88} but its levels are increased by UV-A1 photons through the singlet oxygen activation of the encoded HO-1 gene.\textsuperscript{89,90} and through singlet oxygen-induced reductions in the levels of IFN-gamma, a suppressor of HO-1.\textsuperscript{11}
HO-1 is the 32-kDa rate-limiting enzyme in heme catabolism that degrades the highly oxidizing heme moiety into equimolar amounts of biliverdin, iron, and carbon monoxide (CO). These downstream products of heme catabolism mediate the antioxidant, antiapoptotic, antiproliferative, vasodilatory, and anti-inflammatory effect of HO-1 that gives it restorative potential in patients with lupus. Biliverdin reductase converts biliverdin into bilirubin, and both have potent antioxidant and anti-inflammatory activities as reactive oxygen species scavengers. The oxidant Fe elicits the production of ferritin, which can sequester Fe, making ferritin too, a virtual anti-oxidant. CO, a gas with unique anti-inflammatory, neuroprotective, and mitochondrial actions, has the widest therapeutic potential of all the heme degradation products.

HO-1 is expressed in virtually every cell in the body and is upregulated in mammalian tissues in response to a wide variety of conditions, including vascular and immune injury, ischemia, inflammation, cell cycle dysregulation, and both sublethal and lethal cell damage. The UV-A1-mediated induction of HO-1 expression begins in the skin, the largest organ in the body and the major site of UV exposure. Dermal phospholipids contain polyunsaturated fatty acids that are highly prone to singlet oxygen-induced peroxidation, forming oxidized phospholipids that induce the expression of the HO-1 gene. Although UV-A1 irradiation activates singlet oxygen for only a few nanoseconds, the resulting increase in the HO-1 levels in epidermal cells and cells infiltrating or circulating through the skin lasts for up to three days, sufficient time for HO-1 to act locally and in distant tissues. The low levels of HO-1 in patients with lupus may contribute to the vulnerability of patients to common stressful stimuli, such as viral infections, toxic substances, and lipopolysaccharides, and to their enhanced susceptibility to endothelial damage, all of which are among the aberrations that stand to be remediated by singlet oxygen-generated HO-1.

HO-1 and coronary artery disease

The peak value of HO-1 in lupus may be its impact on coronary artery disease. Patients with lupus have a markedly increased prevalence of coronary artery atherosclerosis and an early age of onset. Consistent with a role for HO-1 in this disease, animals with low HO-1 levels develop myocardial infarctions (MIs) more readily in response to ischemia than animals with normal HO-1 levels. In HO-1 transgenic animals, the frequency of MI is inversely proportional to the level of HO-1. In humans, the HO-1-mediated catalysis of heme, a powerful antioxidant, into the antioxidant biliverdin, which converts into another antioxidant, bilirubin, reduces post-ischemic and post-infarction myocardial dysfunction. Additionally, HO-1 and its product CO promote neovascularization after MI by modulating the expression of hypoxia-inducible factor-1 (HIF-1), stromal cell-derived factor-1 alpha (SDF-1 alpha), and vascular endothelial growth factor-B (VEGF-B).

HO-1 also downregulates hypertension, hyperlipidemia, diabetes, obesity, and atherosclerosis, i.e. metabolic syndrome, actions that contribute to the potential for HO-1 to decrease coronary artery disease. Bilirubin, which is produced from HO-1-generated biliverdin, is negatively associated with hemoglobin A1C levels, metabolic syndrome, and insulin resistance. The capacity of HO-1 to restore homeostasis is well-suited to reverse the disarray induced by coronary artery disease and the metabolic syndrome in patients with lupus.

HO-1 and the central nervous system (CNS)

The effects of HO-1 and its products in the CNS add further to their therapeutic potential in lupus. For a start, full-body UV-A1 irradiation mitigates “brain fog,” a common and often major complaint in patients with lupus. This cognitive dysfunction, which presents as decreased attentiveness, memory deficits, diminished problem-solving capability, and decreases in information organization, is frequently the most immediate and gratifying effect of UV-A1 irradiation therapy. HO-1 exhibits potential neuroprotective effects through the anti-inflammatory, anti-apoptotic, and vasodilatory properties of CO. In concert with nitric oxide (NO), CO bonds to and activates soluble guanylate cyclase (sGC), a heme-containing protein that mediates smooth muscle relaxation, inhibits inflammation, and abrogates ischemic insult to neuronal cells. Increases in the propensity for thrombosis and in cerebral vasospasm are changes observed in the HO-1-deficient mouse. In addition to modulating cerebral vascular resistance, the combination of sGC and
GMP enhances neurotransmission and improves learning and memory, which are commonly impaired in patients with SLE and improved by UV-A1 irradiation.3–9

Packaging CO

The extensive benefits of the homeostatic and cytoprotective actions of CO have prompted an onslaught of research into delivery methods for CO.120–122 In contrast to the currently recommended invasive methods, full-body UV-A1 irradiation is a simpler, safer, gentler, and more physiological means for inducing systemic HO-1. In addition to its effects on lupus, there is compelling evidence that low-dose CO can be therapeutic in a wide array of conditions,123 pointing to a wider usefulness for its progenitor, UV-A1 irradiation.124

Pulmonary disease in SLE

Currently, the only patient with interstitial lung disease (ILD) and pulmonary hypertension (PH) who was treated with UV-A1 irradiation was a 36-year-old Caucasian woman with antinuclear antibody (ANA)/anti-Sjögren syndrome-related antigen A (SSA)-positive lupus for a duration of five years.13 She had been taking 400 mg of hydroxychloroquine and 6 mg of methylprednisolone for the previous year, without a significant effect. Within weeks of starting triweekly full-body UV-A1 irradiation at 8 J/cm², her symptoms of fatigue, malar rash, polyarthritis, mouth ulcers, and intermittent pleurisy abated. The gains were maintained for months with biweekly irradiation treatments, during which time her ILD and PH also responded. She experienced decreases in dyspnea and an increase in the diffusing capacity of the lung for carbon dioxide (DLCO) from 65% to 105% of the predicted value (Figure 3), and her pulmonary artery pressures decreased from 45 to 25 mm Hg. The improvement in both ILD and PH progressed over the years, despite the continued weaning of her corticosteroid treatments from 6 mg to zero per day and the delivery of a healthy baby.

Comment

One team of researchers investigating UV-A1 irradiation reported that four patients with lupus and dyspnea experienced a decrease in their dyspneic symptoms after the UV-A1 irradiation treatment.9 The present investigator treated the only patient with established ILD and PH13 and that patient responded with reversal of the ILD and PH therapy.13 As UV-A1-generated singlet oxygen activates HO-1125 and HO-1 degrades the powerful oxidant heme, splitting it into products with properties capable of inhibiting interstitial inflammation, endothelial apoptosis, and smooth muscle proliferation,126–131 three distinguishing characteristics of ILD/PH, it seems reasonable that it was the UV-A1-induced HO-1 underpinning the resolution of disease in this patient.

To explain more fully, HO-1, in degrading the powerful oxidant heme, releases biliverdin, an antioxidant, which is converted to bilirubin, an antioxidant, and Fe, an inducer of ferritin, another antioxidant, the antioxidants having anti-inflammatory activity.87 CO, through its effects on mitochondrial respiration, downregulates inflammatory processes94 but perhaps as pertinent, CO reverses established PH in mice127 by activating p38 mitogen-activated protein kinase (MAPK).86,128 The activation of p38 MAPK fosters gene-controlled protection of endothelial cells from apoptosis129 and promotes re-endothelialization,85 actions that dampen the rheologic disruption that is often central to PH. CO in addition, increases cGMP, which relaxes smooth muscles in the pulmonary arteries130 and inhibits nuclear factor (NF)-kB-mediated smooth muscle proliferation, both actions running counter to the development of PH.131

Figure 3 Yearly diffusing capacity of the lung for carbon dioxide (DLCO) measurements from the patient receiving 30-minute biweekly, full-body, low-dose ultraviolet (UV)-A1 irradiation at 8 J/cm² for four years at which time the therapy was unavoidably d/c'd, following which the DLCO declined precipitously over the 5th year. CT: computed tomography.
Less direct, but not to be dismissed as contributing to the mitigation of PH and ILD in lupus, is the role of singlet oxygen in reducing the levels of anticardiolipin (aCL) antibodies, which are linked to thrombosis, sometime contributing to the generation of PH, and the singlet oxygen-related decreases in levels of SSA, elevated in patients with lupus and ILD.

In summary, UV-A1 photons appear to have brought reversal of lupus-related ILD/PH through activation of pathways almost perfectly suited for combatting this disease spectrum.

**Subacute cutaneous lupus (SCLE)**

*Comment*

SCLE is a subtype of lupus resulting from apoptosis involving antigen translocation. Normally, following exposure to shorter UV wavelengths, such as UV-B, the extractable nuclear antigens Sjögren syndrome A, Sjögren syndrome B, ribonucleoprotein, and Smith, of human epidermal cells, normally translocate from the nucleus to the cytoplasm and then to the cell membrane during apoptosis. When these antigens reach developing apoptotic blebs in patients with SLE, they bind to their respective circulating autoantibody on the bleb surface, resulting in either antibody-dependent cytotoxicity and cell lysis, or the transport of lupus antigen-antibody complexes into the cell. Lysis results in the release of autoantigens, inflammatory mediators, and viruses into circulation, whereas the transport of antigen-antibody complexes into cells promotes cellular dysfunction. In effect, antibodies to Sjögren syndrome A and other nuclear antigens convert translocation, a physiologic process, into a pathologic one in patients with lupus.

Unlike UV-B and the other shorter wavelengths of UV, UV-A1 wavelengths not only fail to activate translocation but counter this action in SCLE, primarily by triggering immediate apoptosis, which preempts extractable nuclear antigen translocation-induced apoptosis, which is a...
delayed apoptosis. The striking response of SCLE to UV-A1 irradiation is another favorable effect of singlet oxygen-induced immediate apoptosis. This rapid apoptosis eliminates the cell before extractable nuclear antigens can migrate to the membrane blebs to effect lysis. UV-A1 wavelengths also reduce the levels of circulating precipitating SSA antibodies that bind to one of the translocating antigens.5

**Discoid lupus**

UV-A1 therapy reversed discoid lesions in a total of three patients.8,140 However, in the third patient, the discoid lesions were intentionally well-covered during the full-body irradiation.8 Although the reversal in the first two patients indicated a direct effect of the UV-A1 photons, the remission of the covered rash implicated a systemic UV-A1 effect, making discoid lupus, at least in part, a systemic disease and supporting the systemic action of low-dose full body UV-A1 irradiation therapy.

**Antiphospholipid (aPL) antibodies**

A 32-year-old woman with lupus and with high levels of aCL antibodies was treated with long-term, low-dose, full-body UV-A1 irradiation.73 She had a five-year history of progressive memory loss, diminished concentration, and livedo reticularis. Her IgM aCL antibody level was 44 MPL (IgM phospholipid U/ml, normal range: 0–9 MPL/ml), and her IgA and IgG aCL levels were within normal limits. Her score on systemic lupus activity measure–revised (SLAM-R), a validated measure of SLE disease activity, was 14. She was photosensitive, with a malar rash, inflammatory polyarthropathy, chronic cutaneous discoid lupus, and positive for ANA, which comprise the six criteria for the diagnosis of SLE. Her disease began at age 18, with photosensitivity, a malar rash, a biopsy-proven discoid rash and subsequently, severe polyarthritis. Initiation of hydroxychloroquine treatment decreased the joint pain, but not the rash. Intermittent courses of prednisone beginning at age 24 had little effect on her progressive cognitive impairment. At the time of presentation, she was unemployed, having discontinued work because of joint pain, fatigue, memory loss, and other cognitive deficits. She rarely took her hydroxychloroquine, but did use ibuprofen as needed for joint pain. She did not take any other medication. She responded to low-dose, full-body UV-A1 irradiation with a cessation of her progressive dementia, an abatement of the livedo reticularis, a decrease in her aCL levels from 45 to 3 (Figure 5), a reversal of global clinical activity and a cessation of changes in positron-emission tomography during eight months of treatment with biweekly, low-dose (10 J/cm²) UV-A1 irradiation therapy. The sedimentation rate dropped from 37 to 14 Svedberg units, and the ANA and SSA levels were unchanged at 1:640.

The patient’s cognitive function improved as the aCL antibody levels decreased to normal levels and the patient’s symptoms and signs of SLE abated during low-dose, full-body UV-A1 irradiation. Livedo reticularis reversed and both clinical and positron-emission tomography scanning revealed a cessation of the patient’s progressive cognitive decline. The trio of elevated aCL antibodies, livedo reticularis, and cognitive decline constituted an SLE-related antiphospholipid complex. The virtual elimination of this complex with a parallel improvement in the SLAM-R score in the absence of corticosteroid therapy indicated that the full-body UV-A1 therapy was responsible for the improvements.

In a departure from the accepted paradigm that aCL antibodies induce thrombosis, the results of this study are also consistent with an alternative hypothesis for the pathophysiology, namely, that aCL antibodies protect against thrombosis. Phosphatidylcholine (PS) is a membrane component of apoptotic bodies that is a central mediator
of apoptosis. During apoptosis, PS translocates from the cytosolic side of the membrane to its outer surface in a process catalyzed by the enzyme scramblase. Externalized PS facilitates macrophage engulfment by serving as a bridge that enables macrophages to engulf the apoptotic body. However, PS also increases the procoagulant proclivity of apoptotic bodies. When apoptotic bodies abound, the thrombotic propensity increases.

Beta2 glycoprotein 1 (B2GP1), also known as lipoprotein H, is a positively charged phospholipid-binding serum protein that protects against the prothrombotic apoptotic bodies by binding and thus blocking the negatively charged externalized PS responsible for their prothrombotic proclivity. B2GP1 also acts as an opsonin, enhancing the capacity of macrophages to clear the apoptotic bodies. The binding of B2GP1 induces structural changes in both B2GP1 and membrane-bound cardiolipin, precipitating the generation of antibodies directed against both. When bound, these antibodies increase the strength of binding between B2GP1 and the apoptotic bodies 30-fold. The two opsonins facilitate the binding and subsequent engulfment of apoptotic bodies by macrophages, reducing the procoagulant activity of PS in the membrane. This is consistent with the finding that the injection of apoptotic bodies into mice elicits aCL antibody production. The opsonic activity of aCL antibodies may be more effective than most opsonins because of the direct binding of the antibody to the macrophage Fc receptor.

Consistent with an antithrombotic role for aPL antibodies and B2GP1, aCL antibodies and B2GP1 exhibit anticoagulant activity in vitro and in vivo, respectively. In summary, although increases in aCL antibody levels have been thought to play a causative role in coagulopathy and thrombosis, they may instead serve as both a sentinel of and a deterrent to thrombosis.

**Lupus and pregnancy**

The mother and unborn child are protected by the UV-A1-mediated decreases in global systemic disease, as described throughout this manuscript. The removal of apoptotic bodies reduces the thrombotic threat to the placenta. Singlet oxygen-induced activation of HO-1 is of singular value. This enzyme attenuates inflammatory cellular damage in placental villous explants. The induction of HO-1 also compensates for the downregulation of HO-1 in the lupus placenta that predisposes the woman to preeclampsia and recurrent miscarriages. Moreover, the HO-1 products, biliverdin/bilirubin, ferritin, and CO, play augmentative roles in angiogenesis and placental vascular development as well as in the regulation of vascular tone during pregnancy. Elevations of abnormally low HO-1 levels have a telling therapeutic value in pregnant patients with lupus. The UV-A1 irradiation-generated decreases in SSA and aCL antibodies reflect reductions in two major risks in pregnant patients with lupus. Precipitating SSA antibodies are positively associated with neonatal lupus and aCL antibodies are associated with preeclampsia, intrauterine growth retardation, and neonatal antiphospholipid syndrome.

**Summary**

In the first use of long-wavelength UV irradiation for treatment of a systemic disease, UV-A1 wavelengths had a healing action on SLE, a disease known for its toxic sensitivity to the shorter UV wavelengths. The deeply penetrating UV-A1 photons appear to prevent necrosis and restore apoptosis and accelerate the removal of apoptotic bodies, both actions acting to prevent necrosis and its sequelae of inflammation and thrombosis. These long wavelengths also suppress B cell activity, enhance CMI, deter an epigenetic march toward SLE, activate the gene for HO-1, ameliorate SCLE and discoid lupus, attenuate PH and ILD, and are associated with decreases in the levels of aCL antibodies. This noninvasive, readily controlled, and relatively innocuous therapy has benefits that justify its continued use and further research into its effectiveness as a treatment for lupus.

**Declaration of conflicting interests**

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: HM is working with Christopher Macomber, MD, chief medical officer at UV Therapeutics Inc, to convert the fluorescent lamp-based studies described herein to a light-emitting diode-based model. HM has 50,000 shares of indeterminate stock worth a total of $50.00 in this company’s project.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The author received major funding through a Laser Grant from the Louisiana State Board of Regents and four smaller grants from the Louisiana Lupus Foundation in Baton Rouge LA.

References
1 Kocher EV. Acute effects of ultraviolet radiation on the skin. In: Holick MF, Kliger AM (eds), Biologic effects of light. Berlin, New York: Walter de Gruyter & Co, 1992. p. 3.
2 Brainard GC, Beacham S, Sanford BE, Hanifin J, Streletz L, Slinsky D. Near ultraviolet radiation elicits visual evoked potentials in children. Clin Neurophysiol 1999; 110: 379–383.
3 McGrath H Jr, Bak E, Michalski JP. Ultraviolet-A light prolongs survival and improves immune function in (New Zealand black x New Zealand white)F1 hybrid mice. Arthritis Rheum 1987; 30: 557–561.
4 McGrath H Jr, Bak E, Zimny ML, Michalski JP. Fluorescent light decreases autoimmunity and improves immunity in B/W mice. J Clin Lab Immunol 1990; 32: 113–116.
5 McGrath H Jr. Ultraviolet-A1 irradiation decreases clinical disease activity and autoantibodies in patients with systemic lupus erythematosus. Clin Exp Rheumatol 1994; 12: 129–135.
6 McGrath H, Martinez-Osuna P, Lee FA. Ultraviolet-A1 (340–400 nm) irradiation therapy in systemic lupus erythematosus. Lupus 1996; 5: 269–274.
7 Molina JF, McGrath H Jr. Longterm ultraviolet-A1 irradiation therapy in systemic lupus erythematosus. J Rheumatol 1997; 24: 1072–1074.
8 Menon Y, McCarthy K, McGrath H Jr. Reversal of brain dysfunction with UV-A1 irradiation in a patient with systemic lupus. Lupus 2003; 12: 479–482.
9 Polderman MC, le Cessie S, Huizinga TW, Pavel S. Efficacy of UVA-1 cold light as an adjuvant therapy for systemic lupus erythematosus. Rheumatology (Oxford) 2004; 43: 1402–1404.
10 Polderman MC, Huizinga TW, le Cessie S, Pavel S, UVA-1 cold light treatment of SLE: A double blind, placebo controlled cross-over trial. Ann Rheum Dis 2001; 60: 112–115.
11 Szegedi A, Simics E, Alexza M, et al. Ultraviolet-A1 phototherapy modulates Th1/Th2 and Tc1/Tc2 balance in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44: 925–931.
12 McGrath H Jr. Elimination of antidermopilin antibodies and cessation of cognitive decline in a UV-A1-irradiated systemic lupus erythematosus patient. Lupus 2005; 14: 859–861.
13 Jabara B, Dahlgren M, McGrath H Jr. Interstitial lung disease and pulmonary hypertension responsive to low-dose ultraviolet A1 irradiation in lupus. J Clin Rheumatol 2010; 16: 188–189.
14 Attili SK, Dawe RS, Ibbotson SH. Ultraviolet A1 phototherapy: One center’s experience. Indian J Dermatol Venereol Leprol 2017; 83: 60–65.
15 Parrish JA, Jaenicke KF, Anderson RR. Erythema and melanogenesis action spectra of normal human skin. Photochem Photobiol 1982; 36: 187–191.
16 Wu T, Xie C, Han J, et al. Metabolic disturbances associated with systemic lupus erythematosus. PLoS One 2012; 7: e37210.
17 Goettch W, Garssen J, de Gruijl FR, van Loveren H. UV-B and the immune system. A review with special emphasis on T cell-mediated immunity. Thymus 1993; 21: 93–114.
18 Norris DA, Ryan SR, Fritz KA, et al. The role of RNP, Sm, and SS-A/ Ro-specific antisera from patients with lupus erythematosus in inducing antibody-dependent cellular cytotoxicity (ADCC) of targets coated with nonhistone nuclear antigens. Clin Immunol Immunopathol 1984; 31: 311–320.
19 Furukawa F, Kashihara-Sawami M, Lyons MB, Norris DA. Binding of antibodies to the extractable nuclear antigens SS-A/ Ro and SS-B/La is induced on the surface of human keratinocytes by ultraviolet light (UVL): Implications for the pathogenesis of photosensitive cutaneous lupus. J Invest Dermatol 1990; 94: 77–85.
20 Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179: 1317–1330.
21 Reich A, Marcinow K, Biaylnicki-Birula R. The lupus band test in systemic lupus erythematosus patients. Ther Clin Risk Manag 2011; 7: 27–32.
22 Bruls WA, Slaper H, van der Leun JC, Berrens L. Transmission of human epidermis and stratum corneum as a function of thickness in the ultraviolet and visible wavelengths. Photochem Photobiol 1984; 40: 485–494.
23 Elmore S. Apoptosis: A review of programmed cell death. Toxic Pathol 2007; 35: 495–516.
24 Henson PM, Hume DA. Apoptotic cell removal in development and tissue homeostasis. Trends Immunol 2006; 27: 244–250.
25 Savill J, Dransfield I, Gregory C, Haslrett C. A blast from the past: Clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2002; 2: 965–975.
26 Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456–1462.
27 Verhoven B, Schlegel RA, Williamon P. Mechanisms of phosphatidylerosity exposure, a phagocyte recognition signal, on apoptotic T lymphocytes. J Exp Med 1995; 182: 1597–1601.
28 Fadok VA, Henson PM. Apoptosis: Giving phosphatidylserine recognition an assist—with a twist. Curr Biol 2003; 13: R655–R657.
29 Gergely P Jr, Grossman C, Niland B, et al. Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum 2002; 46: 175–190.
30 Fernandez D, Perl A. Metabolic control of T cell activation and death in SLE. Autoimmun Rev 2009; 8: 184–189.
31 Skommer J, Brittain T, Raychaudhuri S. Bcl-2 inhibits apoptosis by increasing the time-to-death and intrinsic cell-to-cell variations in the mitochondrial pathway of cell death. Apoptosis 2010; 15: 1223–1233.
32 Gatenby PA, Irvine M. The bcl-2 proto-oncogene is overexpressed in systemic lupus erythematosus. J Autoimmun 1994; 7: 623–631.
33 Endresen T, Niebur J, et al. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994; 152: 3685–3692.
34 Eguchi Y, Shimizu S, Tsujimoto Y. Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res 1997; 57: 1835–1840.
35 Muñoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 2010; 6: 280–289.
36 Galluzzi L, Morselli E, Vicencio JM, et al. Life, death and burial: Multifaceted impact of autophagy. Biochem Soc Trans 2008; 36 (Pt 5): 786–790.
37 Godar DE. Reprogrammed and programmed cell death mechanisms of apoptosis: UV-induced immediate and delayed apoptosis. Photochem Photobiol 1996; 63: 875–830.
38 Godar DE. Singlet oxygen-triggered immediate preprogrammed apoptosis. Methods Enzymol 2000; 319: 309–330.
39 Glick D, Barth S, MacLeod KF. Autophagy: cellular and molecular mechanisms. J Pathol 2010; 221: 3–12.
40 Zhao Y, Zhang CF, Rossiter H, et al. Autophagy is induced by UV and promotes removal of oxidized phospholipids and protein aggregates in epidermal keratinocytes. J Invest Dermatol 2013; 133: 1629–1637.
41 Breuckmann F, Pieck C, Kreuter A, et al. Opposing effects of UV1A phototherapy on the expression of bcl-2 and p53 in atopic dermatitis. Arch Dermatol Res 2001; 293: 178–183.
42 Cohen JJ, Duke RC, Fadok VA, Sellins KS. Apoptosis and programmed cell death in immunity. Ann Rev Immunol 1992; 10: 267–293.
43 Cohen PL, Caricchio R, Abraham V, et al. Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med 2002; 196: 135–140.

44 Tsai-Turton M, Luong BT, Tan Y, Luderer U. Cyclophosphamide-induced apoptosis in COV434 human granulosa cells involves oxidative stress and glutathione depletion. Toxicol Sci 2007; 98: 216–230.

45 Meng WX, Feller JM, Ziegler JB, Pittman SM, Ireland CM. Induction of apoptosis in peripheral blood lymphocytes following treatment in vitro with hydroxychloroquine. Arthritis Rheum 1997; 40: 927–935.

46 Cohn RG, Mirkovich A, Dunlap B, et al. Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation 1999; 68: 411–418.

47 Stohl W, Hilbert DM. The discovery and development of belimumab: The anti-BLYS-lupus connection. Nat Biotechnol 2012; 30: 69–77.

48 Almoallim H, AlGhamdi Y, Almarghabi H, Alyasi O. Anti-tumor necrosis factor-α-induced systemic lupus erythematosus (SLE). Open Rheumatol J 2006; 2: 315–319.

49 Theofilopoulos AN, Koundouris S, Kono DH, Lawson BR. The role of IFN-γ in systemic lupus erythematosus: A challenge to the Th1/Th2 paradigm in autoimmunity. Arthritis Res 2001; 3: 136–141.

50 Harigai M, Kawamoto M, Hara M, Kubota T, Kamatani N, Miyasaka N. Excessive production of IFN-γ in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B. J Immunol 2008; 181: 2211–2219.

51 Do KK, Chen-Kiang S. Mechanism of Blys action in B cell immunity. Cytokine Growth Factor Rev 2002; 13: 19–25.

52 Collins CE, Gavin AL, Migone TS, Hilbert DM, Nemazee D, Stohl W. B lymphocyte stimulator (BLYS) isoforms in systemic lupus erythematosus: Disease activity correlates better with blood leukocyte BLYS mRNA levels than with plasma BLYS protein levels. Arthritis Res Ther 2006; 8: R6.

53 Vadasa Z, Toubi E. Belimumab—the biological drug for systemic lupus erythematosus: As discussed during the American College of Rheumatology (ACR) conference—2012 [article in Hebrew]. Harefuah 2013; 152: 304–306.

54 Beer JZ, Olvey KM, Miller SA, Thomas DP, Godar DE. Non-nuclear damage and cell lysis are induced by UVa, but not UVb or UVc, radiation in three strains of L5178Y cells. Photochem Photobiol 1993; 58: 676–681.

55 Godar DE, Miller SA, Thomas DP. Immediate and delayed apoptotic cell death mechanisms: UVa versus UVb and UVc radiation. Cell Death Differ 1994; 1: 59–66.

56 Polderman MC, van Kooten C, Smit NP, Kamerling SW, Pavel S. Ultraviolet-A (UVA-1) radiation suppresses immunoglobulin production of activated B lymphocytes in vitro. Clin Exp Immunol 2006; 145: 528–534.

57 Benninghoff B, Dröge W, Lehmann V. The lipopolysaccharide-induced stimulation of peritoneal macrophages involves at least two signal pathways. Partial stimulation by lipid A precursors. Eur J Biochem 1989; 179: 589–594.

58 Allanson M, Reeve VE. Ultraviolet A (320–400 nm) modulation of ultraviolet B (290–320 nm)-induced immune suppression is mediated by carbon monoxide. J Invest Dermatol 2005; 124: 644–650.

59 Horwitz DA. Impaired delayed hypersensitivity in systemic lupus erythematosus. Arthritis Rheum 1972; 15: 353–359.

60 Noonan FP, De Fabo EC, Kripke ML. Suppression of contact hypersensitivity by ultraviolet radiation: An experimental model. Springer Semin Immunopathol 1981; 4: 293–304.

61 Ulrich SE, Azizi E, Kripke ML. Suppression of the induction of delayed-type hypersensitivity reactions in mice by a single exposure to ultraviolet radiation. Photochem Photobiol 1986; 43: 633–638.

62 Reeve VE, Bosnic M, Boehm-Wilcox C, Nishimura N, Ley RD. Ultraviolet A radiation (320–400 nm) protects hairless mice from immunosuppression induced by ultraviolet B radiation (290–320 nm) or cis-uroc acid. Int Arch Allergy Immunol 1998; 115: 316–322.

63 Garsen J, de Gruij L, Mol D, de Klerk A, Rohlff P, Van Loveren H. UVa exposure affects UVB and cis-uroc acid-induced systemic suppression of immune responses in Listeria monocytogenes-infected Balb/c mice. Photochem Photobiol 2001; 73: 432–438.

64 Hager Ed, Benninghoff B, Pakdaman A, Stickl A, Mutzhas MF. Verbesserung zellvermittelter Immunitat bei Tuormpatienten durch hochdosierte Phototherapie mit langwelligem Ultraviolet A (UV-A1). Deutsches Zeitschrift fur Onkologie 1989; 2: 42–49.

65 Gibbs NK, Norval M. Uric acid in the skin: A mixed blessing? Br J Dermatol 2011; 164: 141–17.

66 Rhiner M, McGrath H Jr. Fluorescent light photosensitivity in patients with systemic lupus erythematosus. Arthritis Rheum 1992; 35: 949–952.

67 Menon EL, Morrison H. Formation of singlet oxygen by urocanic acid by UVA irradiation and some consequences thereof. Photochem Photobiol 2002; 75: 565–569.

68 Ryter SW, Morse D, Choi AM. Carbon monoxide: To boldly go where NO has gone before. Sci STKE 2004; 2004: RE6.

69 Verma A, Hirsch DJ, Glatt CE, Ronnett GV, Snyder SH. Carbon monoxide: A putative neural messenger. Science 1993; 259: 381–384.

70 Allanson M, Domanski D, Reeve VE. Photoimmunoprotection by UVa (320–400 nm) radiation is determined by UVA dose and is associated with cutaneous cyclic guanosine monophosphate. J Invest Dermatol 2006; 126: 191–197.

71 Javierre BM, Fernandez AF, Richter J, et al. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res 2010; 20: 170–179.

72 Zhang Y, Zhao M, Sawalha AH, Richardson B, Lu Q. Impaired DNA methylation and its mechanisms in CD4+ T cells of systemic lupus erythematosus. J Autoimmun 2013; 41: 92–99.

73 Wu H, Zhao M, Tan L, Lu Q. The key culprit in the pathogenesis of systemic lupus erythematosus: Aberrant DNA methylation. Autoimmun Rev 2016; 15: 684–689.

74 Renaudineau Y, Beauvillard D, Padelli M, Brooks WH, Youinou P. Epigenetic alterations and autoimmune disease. J Dev Orig Health Dis 2011; 2: 258–264.

75 Zouali M. Epigenetics in lupus. Ann N Y Acad Sci 2011; 1217: 154–165.

76 Renaudineau Y, Youinou P. Epigenetics and autoimmunity, with special emphasis on methylation. Keio J Med 2011; 60: 10–16.

77 Liang F, Cao J, Qin WT, Wang X, Qiu XF, Sun BW. Regulatory effect and mechanisms of carbon monoxide-releasing molecule II on hepatic energy metabolism in septic mice. World J Gastroenterol 2014; 20: 3301–3311.

78 Deng C, Kaplan MJ, Yang J, et al. Decreased Ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum 2001; 44: 397–407.

79 Coit P, Jeffries M, Altorko N, et al. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naive CD4+ T cells from lupus patients. J Autoimmun 2012; 39: 78–84.

80 Jeffries MA, Dozmorov M, Tang Y, Merrill JT, Wren JD, Sawalha AH. Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus. Epigenetics 2011; 6: 593–601.

81 Attwood JT, Yung RL, Richardson BC. DNA methylation and the regulation of gene transcription. Cell Mol Life Sci 2002; 59: 241–257.

82 Abshire DM, Li X, Waite LL, et al. Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations. PLoS Genet 2013; 9: e1003678.

83 Jeffries MA, Dozmorov M, Tang Y, Merrill JT, Wren JD, Sawalha AH. Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus. Epigenetics 2011; 6: 593–601.

84 Wu Z, Li X, Qin H, Zhu X, Xu J, Shi W. Ultraviolet B enhances DNA hypomethylation of CD4+ T cells in systemic lupus erythematosus via inhibiting DNMT1 catalytic activity. J Dermatol Sci 2013; 71: 167–173.
infarction by modulating the expression of HIF-1alpha, SDF-1alphad and VEGF-B. *Eur J Pharmacol* 2010; 635: 156–164.

90. Levitt DG, Levitt MD. Carbon monoxide: A critical quantitative analysis and review of the extent and limitations of its second messenger function. *Clin Pharmacol 2015; 7: 37–56.

91. Chung CP, Oeser A, Solus JF, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. *Atherosclerosis* 2008; 196: 756–763.

92. Yoshino S, Hamasaki S, Ishida S, et al. Relationship between bilirubin concentration, coronary endothelial function, and inflammatory stress in overweight patients. *J Atheroscler Thromb* 2011; 18: 403–412.

93. Guzek M, Jakubowski Z, Bandoz P, et al. Inverse association of serum bilirubin with metabolic syndrome and insulin resistance in Polish population. *Przegl Epidemiol* 2012; 66: 495–501.

94. Motterlini R, Clark JE, Foresti R, Motterlini R. CORM-3, a carbon monoxide-releasing molecule, alters the inflammatory response and reduces brain damage in a rat model of hemorrhagic shock. *Crit Care Med* 2012; 40: 544–552.

95. Willins D, Moore AR, Frederick R, Willoughby DA. Heme oxygenase: A novel target for the modulation of the inflammatory response. *Nat Med 1996; 2: 87–90.

96. Vieira HL, Queiroga CS, Alves PM. Pre-conditioning induced by carbon monoxide provides neural protection against apoptosis. *J Neurochem* 2008; 107: 375–384.

97. Hernandez-Viadel M, Castoldi AF, Cocci T, Manzo L, Ereng S, Felipo V. In vivo exposure to carbon monoxide causes delayed impairment of activation of soluble guanylate cyclase by nitric oxide in rat brain cortex and cerebellum. *J Neurochem* 2004; 89: 1157–1165.

98. Sharma VS, Magde D. Activation of soluble guanylate cyclase by carbon monoxide and nitric oxide: A mechanistic model. *Methods 1999; 19: 494–505.

99. Schallner N, Otterbein LE. Friend or foe? Carbon monoxide and immunosuppression. *Proc Natl Acad Sci U S A 1997; 94: 10925–10930.

100. Bani-Hani MG, Greenstein D, Mann BE, Green CJ. Carbon monoxide-releasing molecules: Characterization of biochemical and vascular activities. *Circ Res 2002; 90: E17–E24.

101. Rieder SW, Otterbein LE. Carbon monoxide in biology and medicine. *Bioessays 2004; 26: 270–280.

102. Motterlini R, Otterbein LE. The therapeutic potential of carbon monoxide. *Nat Rev Drug Discov 2010; 9: 728–743.

103. Tyrrell RM. Solar ultraviolet A radiation: An oxidizing skin carcinogen that activates heme oxygenase-1. *Antioxid Redox Signal* 2004; 6: 835–840.

104. Motterlini R, Otterbein LE. The therapeutic potential of carbon monoxide. *Eur J Pharmacol 2009; 636: 544–552.

105. Chung CP, Oeser A, Solus JF, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. *Atherosclerosis* 2008; 196: 756–763.

106. Yoshino S, Hamasaki S, Ishida S, et al. Relationship between bilirubin concentration, coronary endothelial function, and inflammatory stress in overweight patients. *J Atheroscler Thromb* 2011; 18: 403–412.

107. Guzek M, Jakubowski Z, Bandoz P, et al. Inverse association of serum bilirubin with metabolic syndrome and insulin resistance in Polish population. *Przegl Epidemiol* 2012; 66: 495–501.

108. Motterlini R, Clark JE, Foresti R, Motterlini R. CORM-3, a carbon monoxide-releasing molecule, alters the inflammatory response and reduces brain damage in a rat model of hemorrhagic shock. *Crit Care Med* 2012; 40: 544–552.
et al
134 LeFebet WP, Norris DA, Ryan SR, Golan TD, Elkon KB, Gharavi AE, Krueger JG. Enhanced membrane binding of autoantibodies to cultured keratinocytes of systemic lupus erythematosus patients after ultraviolet B/ultraviolet A irradiation. J Clin Invest 1992; 90: 1067–1076.
135 LeFeber WP, Norris DA, Ryan SR, et al. Ultraviolet light induces binding of antibodies to selected nuclear antigens on cultured human keratinocytes. J Clin Invest 1984; 74: 1545–1551.
136 Rosen A, Casciola-Rosen L, Ahearn J. Novel packages of viral nucleic acid binding and anti-cardiolipin antibody activity. J Immunol 1996; 157: 3744–3751.
137 Norris DA. Pathomechanisms of photosensitive lupus erythematosus. J Invest Dermatol 1995; 181: 1557–1561.
138 Lee LA, Norris DA. Mechanisms of cutaneous tissue damage in systemic lupus erythematosus. J Exp Med 1989; 16: 359–386.
139 So¨nnichsen N, Meffert H, Kunzelmann V, Audring H. UV-A-1 irradiation. Biochim Biophys Acta 2000; 1509: 475–484.
140 Mitra A, Yung A, Goulden V, Goodfield MD. A trial of low-dose heme oxygenase-1 therapy of subacute cutaneous lupus erythematosus [article in German]. Hautarzt 1993; 44: 723–725.
141 Shaw AW, Pureza VS, Sligar SG, Morrissey JH. The local phospholipid environment modulates the activation of blood clotting. J Biol Chem 2007; 282: 6556–6563.
142 Sahu SK, Gummadi SN, Manoj N, Aradhya CM. Phospholipid scramblases: An overview. Arch Biochem Biophys 2007; 462: 103–114.
143 Gaipl US, Munoz LE, Grossmayer G, et al. Clearance deficiency and systemic lupus erythematosus (SLE). J Autoimmun 2007; 28: 114–121.
144 Martin SJ, Finucane DM, Amarante-Mendes GP, O’Brien GA, Green DR. Phosphatidylserine externalization during CD95-induced apoptosis of cells and cytoplasm requires ICE/CED-3 protease activity. J Biol Chem 1996; 271: 28753–28756.
145 Sorice M, Cirrella A, Misasi R, et al. Cardiolipin on the surface of apoptotic cells as a possible trigger for antiphospholipid antibodies. Clin Exp Immunol 2000; 122: 277–284.
146 Spronk HM, ten Cate H, van der Meijden PE. Differential roles of tissue factor and phosphatidylserine in activation of coagulation. Thromb Res 2014; 133 (Suppl 1): S54–S56.
147 Gao C, Xie R, Yu C, et al. Thrombotic role of blood and endothelial cells in uremia through phosphatidylserine exposure and microparticle release. PloS One 2015; 10: e0142835.
148 Borchman D, Harris EN, Pierangeli SS, Lamba OP. Interactions and molecular structure of cardiolipin and beta 2-glycoprotein 1 (beta 2-GP1). Clin Exp Immunol 1995; 102: 373–378.
149 Maiti SN, Balasubramanian K, Ramoth JA, Schroit AJ. Beta-2-glycoprotein 1-dependent macrophage uptake of apoptotic cells. Binding to lipoprotein receptor-related protein receptor family members. J Biol Chem 2008; 283: 3761–3766.
150 Lee AT, Balasubramanian K, Schroit AJ. beta(2)-glycoprotein 1-dependent alterations in membrane properties. Biochim Biophys Acta 2000; 1509: 475–484.
151 Willems GM, Janssen MP, Pelsers MM, et al. Role of divalency in the high-affinity binding of anticardiolipin antibody-beta 2-glycoprotein I complexes to lipid membranes. Biochemistry 1996; 35: 13833–13842.
152 Sheng Y, Sali A, Herzog H, Lahnstein J, Krilis SA. Site-directed mutagenesis of recombinant human beta 2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity. J Immunol 1996; 157: 3744–3751.
153 Manfredi AA, Rovere P, Galati G, et al. Apoptotic cell clearance in systemic lupus erythematosus. I. Opsonization by antiphospholipid antibodies. Arthritis Rheum 1998; 41: 205–214.
154 Hart SP, Smith JR, Dransfield I. Phagocytosis of opsonized apoptotic cells: Roles for ‘old-fashioned’ receptors for antibody and complement. Clin Exp Immunol 2004; 135: 181–185.
155 Mevorach D, Zhou JL, Song X, Elkson KB. Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med 1998; 188: 387–392.
156 Dorrington KJ. Properties of the Fc receptor on macrophages. Immunol Commun 1976; 5: 263–280.
157 Schousboe I, Rasmussen MS. Synchronized inhibition of the phospholipid mediated autocytolysis of factor XII in plasma by beta 2-glycoprotein I and anti-beta 2-glycoprotein I. Thromb Haemost 1995; 73: 798–804.
158 Stiel’TW, Kurz J, Doss MO, Fareed J. Singlet oxygen inactivates fibrinogen, factor V, factor VIII, factor X, and platelet aggregation of human blood. Thromb Res 2000; 97: 473–480.
159 Lopez LR, Dier KJ, Lopez D, Merrill JT, Fink CA. Anti-beta 2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Am J Clin Pathol 2004; 121: 142–149.
159 Ahmed A, Rahman M, Zhang X, et al. Induction of placental heme oxygenase-1 is protective against TNFalpha-induced cytotoxicity and promotes vessel relaxation. Mol Med 2000; 6: 391–409.
161 Zenclussen AC, Sollwedel A, Bertoja AZ, et al. Heme oxygenase as a therapeutic target in immunological pregnancy complications. Int Immunopharmacol 2005; 5: 41–51.
160 Ozen M, Zhao H, Lewis DB, Wong RJ, Stevenson DK. Heme oxygenase and the immune system in normal and pathological pregnancies. Front Pharmacol 2015; 6: 84.
162 Ozen M, Zhao H, Lewis DB, Wong RJ, Stevenson DK. Heme oxygenase and the immune system in normal and pathological pregnancies. Front Pharmacol 2015; 6: 84.
163 Lee LA. Transient autoimmunity related to maternal autoantibodies. Lupus 2014; 14: 207–213.
164 Abreu MM, Danowski A, Wahl DG, et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev 2015; 14: 401–414.